SCHEMBL29890102

SCHEMBL29890102

Cc1ncc(Br)cc1F

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663357 1.00
Hydrochloric Acid SCHEMBL21580793 0.98 SMN1; SMN2 (0.37)
SCHEMBL31378559 0.78 GABRG2 (0.36)
SCHEMBL29520643 0.75
SCHEMBL502594 0.75
SCHEMBL29845509 0.75
SCHEMBL663225 0.75
SCHEMBL4137228 0.75
SCHEMBL29751880 0.75
SCHEMBL29475255 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024240213-A1 FUSED TRICYCLIC SUBSTITUTED ISOXAZOLIDINYL UREA DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 上海海雁医药科技有限公司 2024-11-28 WO disclosed
US-11939327-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-03-26 US disclosed
EP-3693360-B1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICALS CO (JP) 2023-12-13 EP disclosed
US-20230278999-A1 HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-09-07 US disclosed
EP-4073062-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-10-19 EP disclosed
EP-4073063-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-10-19 EP disclosed
US-11447488-B2 Heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-09-20 US disclosed
EP-4045025-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2022-08-24 EP disclosed